Beyond Markets

The development of drugs to treat obesity brings a number of questions to the fore. How can medication actually help us to lose weight, what is the potential market size, and what long-term effects might these drugs have on our lives and on healthcare and various other sectors. In this episode of the Beyond Markets podcast, Helen Freer, Investment Writer, talks about these questions and more with Fabian Wenner, Equity Analyst, and Philipp Lienhardt, Head of Equity Research.

01:08 The potential market size
01:54 The global economic impact of obesity
03:05 How do obesity drugs work?
04:27 What are the potential side-effects and longer-term effects?
05:42 A pill version of the drug
06:32 Two types of customers: diabetes patients and those suffering from obesity
08:13 How expensive is the medication?
09:39 What effect might these drugs have on our lives?
10:01 Benefits for cardiovascular health
10:38 Cross-sector analysis
 

What is Beyond Markets?

“Beyond Markets” by Julius Baer is a series featuring conversations with experts to share recent market developments, key insights, and strategic inputs from around the globe. In each episode, we cut through the noise to offer practical advice and macro research on today’s shifting economic and market landscape.
The information contained in this podcast is marketing material. Opinions expressed do not constitute independent financial/investment research, investment advice, or an offer to buy or sell securities by Julius Baer. Please refer to www.juliusbaer.com/legal/podcasts for important legal information prior to listening to this podcast.